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Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston
There is a critical need to understand why missense mutations are deleterious. The deleterious effects of missense
mutations are commonly attributed to their impact on primary amino acid sequence and protein structure.However,
several recent studies have shown that some missense mutations are deleterious because they disturb cis-acting
splicing elements—so-called “exonic splicing enhancers” (ESEs). It is not clear whether the ESE-related deleterious
effects of missense mutations are common. We have evaluated colocalization of pathogenic missense mutations
(found in affected individuals) with high-score ESE motifs in the human mismatch-repair genes hMSH2 and hMLH1.
We found that pathogenic missense mutations in the hMSH2 and hMLH1 genes are located in ESE sites signiﬁcantly
more frequently than expected. Pathogenic missense mutations also tended to decrease ESE scores, thus leading to
a higher propensity for splicing defects. In contrast, nonpathogenic missense mutations (polymorphisms found in
unaffected individuals) and nonsense mutations are distributed randomly in relation to ESE sites. Comparison of
the observed and expected frequencies of missense mutations in ESE sites shows that pathogenic effects of 20%
of mutations in hMSH2 result from disruption of ESE sites and disturbed splicing. Similarly, pathogenic effects of
16% of missense mutations in the hMLH1 gene are ESE related. The colocalization of pathogenicmissensemutations
with ESE sites strongly suggests that their pathogenic effects are splicing related.
Missense mutations—nucleotide substitutions that
change an amino acid in a protein—are among the most
common types of mutations underlying inherited human
diseases. The deleterious effects of missense mutations
are usually attributed to their effects on protein function.
However, recent studies of normal and alternative splic-
ing suggest that the deleterious effects of nucleotide sub-
stitutions might, in fact, be splicing related when they
are located in exonic splicing enhancers (ESEs) (Cartegni
and Krainer 2002; Cartegni et al. 2002; Fackenthal et
al. 2002; Moseley et al. 2002; Pollard et al. 2002). ESEs
are discrete, degenerate motifs of 6–8 nts located inside
exons (Liu et al. 1998; Blencowe 2000). The study of nor-
mal splicing suggests that most exons contain at least one
functional ESE site (Blencowe 2000;Hastings andKrainer
2001; Cartegni et al. 2002). ESEs are target sequences for
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the family of conserved essential splicing factors—the ser-
ine- and arginine-rich (SR) proteins (Stojdl and Bell 1999;
Graveley 2000; Hastings and Krainer 2001). ESEs play
an important role in exon recognition. Nucleotide substi-
tutions in ESEs can result in failure of SR proteins to bind
to the ESE, which leads to failure of splisosomemachinery
to recognize the sequence as exonic and causes exon skip-
ping (Ars et al. 2000; Cartegni et al. 2002; Fackenthal et
al. 2002;Moseley et al. 2002). Each SR protein recognizes
speciﬁc, albeit degenerate and partially redundant, se-
quence motifs. ESE motifs for four members of the SR
family (SF2/ASF, SRp40, SRp55, and SC35) have been
identiﬁed (Liu et al. 1998; Stojdl and Bell 1999; Graveley
2000; Liu et al. 2000). To identify the ESE motifs that
are recognized by individual SR proteins, a PCR-based
approach called “SELEX” (systematic evolution of li-
gands by exponential) enrichment was used. In this ap-
proach, a natural splicing enhancer in a minigene is re-
placed by short, random sequences derived from an
oligonucleotide library. The generated pool of minigenes
is transfected into cultured cells, and spliced mRNAs are
ampliﬁed by RT-PCR and sequenced (Liu et al. 1998,
2000). On the basis of the frequencies of the individual
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Table 1
Types and Numbers of Mutations Analyzed
GENE
NO. OF MUTATIONS
TOTAL
MUTATIONSPathogenic Missense
Nonsense and
Frameshift
Nonpathogenic
Missense
hMSH2 50 81 17 148
hMLH1 99 68 8 175
nucleotides at each position, a score matrix for each
nucleotide in each position was calculated. This score
matrix can be used to predict SR protein–speciﬁc ESEs
(ESEﬁnder).
We studied the association of pathogenicmissensemu-
tations (found in affected kindreds), nonpathogenic mis-
sense mutations (polymorphic mutations and sequence
variants found in nonaffected individuals), nonsense mu-
tations, and frameshifts (here restricted to 1- or 2-nt de-
letions and insertions) with ESE sites in hMSH2 and
hMLH1, human mismatch repair genes that are related
to human nonpolyposis colon cancer (HNPCC [MIM
114500]) (Peltomaki andVasen 1997).We used published
and our own data on pathogenic and nonpathogenic mis-
sense mutations in the hMSH2 and hMLH1 genes (tables
A, B, C, D, and E [online only]). Only mutations found
in independent families were used. We excluded multiple
reported mutations found in the same family. The num-
bers of different types of mutations analyzed are shown
in table 1.
First, we searched the coding regions of the genes for
the presence of ESE motifs with ESEﬁnder software. To
reduce the number of false-positive results, we used a
more-stringent-than-recommended threshold value of 3.0
for all four types of ESE motifs. Potential ESE motifs
found in the hMSH2 and hMLH1 genes are listed in
table E (online only). We excluded ESEs in exon/exon
boundaries, accounted for overlap between different ESEs
by counting as a single ESE any segment containing two
or more ESEs, and estimated the percentage of sequence
that consists of ESE motifs for each entire gene and each
exon. This estimate provided us with the proportion of
mutations expected to be in ESE motifs under the null
hypothesis that assumes that there is no association be-
tween pathogenic missense mutations and exonic splicing
enhancers.
Different nucleotide substitutions in mutation data-
bases for the hMSH2 and hMLH1 genes differ with re-
spect to how many times they are reported in the data-
bases. Some of them are listed only once, whereas others
are reported several times (e.g., the CrT transition at
position 350 in the hMLH1 gene is reported 11 times).
Multiply reported mutations in the mutation databases
originate from different families. Counting each reported
mutation, we found that missense mutations are colo-
calized with ESEs (for hMSH2, , ,2x p 11.8 dfp 1
; for hMLH1, , , ) (ﬁg.2P ! .001 x p 7.9 dfp 1 P ! .01
1a). Alternatively, we also counted each separatemutation
only once, no matter how often it was listed in the data-
base. Again, we found that, in both genes, deleterious
missense mutations are located in ESEs more frequently
than expected (for hMSH2, , , ;2x p 9.4 dfp 1 P ! .001
for hMLH1, , , ). Counting each2x p 4.3 dfp 1 P ! .05
mutation only once eliminates all possibility that families
are related but probably leads to a downward bias. Nu-
cleotide substitutions can occur at any position in a cod-
ing region of a gene; yet only deleterious mutations that
disturb important functional sites would lead to cancer
and thus have a chance of being detected by screening
of cancer-affected families. The more deleterious themu-
tation, the higher the chance it has of causing disease
and of being detected. Therefore, deleterious mutations
are expected to be most frequent in mutation databases
(Martin et al. 2002; Olivier et al. 2002). Counting mul-
tiple mutations only once leads to loss of information
and may cause downward bias by reducing the number
of observations and by eliminating variation in the num-
ber of mutations between different mutant sites.
There may be two possible explanations for missense
mutations in hMSH2 and hMLH1 genes being prefer-
entially located in ESE motifs: either missense mutations
arise more frequently in ESEs, or mutations in ESEs are
more pathogenic than mutations outside ESEs and there-
fore are more likely to be detected during screening of
affected individuals. Our analysis favors the second ex-
planation. If a missense mutation becomes pathogenic be-
cause it is located in an ESE, then one can expect patho-
genic missense mutations to be located in ESE sites more
frequently, comparedwith nonpathogenic ones.We found
that 57% (28/49) of pathogenic missense mutations were
located in ESEs of the hMSH2 gene versus 24% (4/17)
of nonpathogenic mutations ( ; ;2x p 5.66 Pp .021
Fisher’s exact test). For the hMLH1 gene, we also found
that pathogenic missense mutations were more frequently
located in ESE sites than nonpathogenicmutations—58%
(57/99) versus 38% (3/8), respectively ( ;2x p 1.21 Pp1
; Fisher’s exact test)—but there were too few non-.30
pathogenic mutations to draw a meaningful conclusion.
If deleterious effects of nucleotide substitutions located
inside ESE motifs result from disruption of splicing, then
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Figure 1 a, Frequency of ESE-associated mutations. Horizontal lines show the expected frequencies of mutations calculated as a proportion
of the sequence occupied by ESE motifs. Differences between the expected and observed frequencies of pathogenic missense mutations (PM) were
signiﬁcant for both hMSH2 and hMLH1 (marked by an asterisk [*]). Nonpathogenic missense mutations (NP) show a trend to be underrepresented
in ESEs. Nonsense and frameshift mutations (NF) did not show preferential association with ESE sites. Bars represent SEs of the frequencies. b,
Positions of pathogenic missense mutations with respect to the 5′ and 3′ ends of an exon. The last 20 nts of exons had the highest frequency of
mutations in ESEs: 83% of the mutations were in ESE sites (marked by a double asterisk [**]). The difference between the observed and
expected numbers of mutations in that region was highly signiﬁcant ( ; ; ). When the analysis was limited to short2x p 33.8 dfp 1 P ! .001
(average size, 80 nts) exons, the colocalization of the pathogenic missense mutations with ESE sites was even higher: 96% of the mutations
were in ESEs.
even missense mutations that are unlikely to affect protein
structure (e.g., mutations that do not change the type of
amino acid) will have a chance to be deleterious because
they disturb ESEs and, therefore, splicing. This idea is
supported by stratiﬁed analysis. We stratiﬁed missense
mutations into “conservative” and “radical” (classifying
them according to speciﬁcations of Dagan et al. [2002]),
and we found that, in both genes, missense mutations
located outside ESE sites tended to be “radical,” strongly
affecting protein-structure mutations, whereas those lo-
cated in ESE motifs are more likely to be “conservative”
mutations that have no or slight effect on protein struc-
ture. For hMSH2 genes, the frequency of conservative
missense mutations located in ESEs is 0.610.09,
whereas the frequency of conservativemissensemutations
outside ESEs is 0.500.10. For the hMLH1 gene, we
found the same trend: the frequency of conservative mis-
sense mutations in ESEs is 0.310.06, whereas the
frequency of conservative mutations outside ESEs is
0.210.10. For both genes, the differences in the pro-
portions of conservativemissensemutations located inside
and outside of ESE sites are not signiﬁcant, even after we
combine the data for both genes, probably because of the
relatively low number of mutations in analysis.
The correlation of different types ofmutationswithESE
sites can be explained as follows: nonsense and frameshift
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mutations always produce truncated nonfunctional pro-
teins and therefore always—no matter where they are lo-
cated with respect to ESEs—are sufﬁciently damaging
to cause disease. Thus, truncating mutations have a high
chance of being detected by screening affected families.
Missense mutations, especially those located outside im-
portant functional domains, may not change protein
structure sufﬁciently to be pathogenic. However, if a nu-
cleotide substitution occurs in a functional ESE site, it
could disturb normal splicing and be sufﬁciently delete-
rious to cause disease. This could explain why affected
individuals are enriched with missense mutations that are
located in ESE sites and why polymorphisms found in
unaffected individuals are not associated with ESEs and
even show a trend not to be localized there.
Different single-nucleotide substitutions can change the
ESE score in different directions: some substitutions in-
crease the score, whereas others decrease it. If nucleotide
substitutions located in ESE sites are deleterious because
they disturb functional ESE sites, then such substitutions
are expected mainly to decrease ESE scores. We com-
pared the observed and expected proportion of score-
decreasing missense mutations located inside ESE sites.
The expected proportion of score-decreasing substitu-
tions was calculated on the basis of all possible substitu-
tions in the ESEs that lead to missense mutations. We
found that ESE-located missense mutations reported in
hMSH2 and hMLH1 mutation databases decrease ESE
scores signiﬁcantly more frequently than one would ex-
pect. For the hMSH2 gene, we found that the expected
frequency of score-decreasing mutations is 0.770.03,
whereas the observed frequency of score-decreasingmu-
tations is 0.960.04. The differences are highly signiﬁ-
cant ( ; ; ). A similar result was2x p 6.5 dfp 1 P ! .01
obtained for the hMLH1 gene: the expected frequency
of score-decreasing mutations is 0.780.02, whereas
the observed frequency of score-decreasing mutations is
0.910.06 ( ; ; ).2x p 5.9 dfp 1 P ! .01
The excess of pathogenic mutations in ESE sites com-
pared with the expected frequency provides a minimal
estimate of the proportion of missense mutations, the
pathogenic effects of which are ESE related. As an upper
limit for the estimate of the proportion of ESE-related
mutations, one can suggest that all pathogenic missense
mutations located in ESE sites are deleterious because they
disturb functional splicing enhancers. This approach is
likely to overestimate the proportion of ESE-related
pathogenic mutations. First, not all ESEmotifs are actual
functional splicing enhancers (Cartegni 2002). Second,
not all nucleotide substitutions in functional ESEs dis-
turb their function (Cartegni and Krainer 2002; Fack-
enthal et al. 2002;Moseley et al. 2002; Pollard et al. 2002;
ESEﬁnder). For the hMSH2 gene, the observed frequency
of pathogenic missense mutations in ESEs is 55%,
whereas the expected frequency is 36%. This means that
20%–55% of missense mutations in hMSH2 are path-
ogenic, because they affect ESE sites and therefore dis-
turb normal splicing. A similar reasoning shows that the
frequency of ESE-related mutations in the hMLH1 gene
is 16%–58%.
Although an exon usually has several ESE motifs, the
splicing machinery does not use most of them (Cartegni
2002; ESEﬁnder). The question is whether the functional
ESE sites are distributed randomly. If functional ESEs are
preferentially located in some speciﬁc regions within an
exon, then the association of the pathogenic missense
mutations with ESEs will be higher in that region. A
study of the molecular mechanisms of splicing suggests
that functional ESE sites occupy speciﬁc positions rela-
tive to the 5′ or 3′ ends of an exon (Blencowe 2000;
Hastings and Krainer 2001; Cartegni et al. 2002). We
compared the expected and observed frequencies of
pathogenic missense mutations in four regions: the ﬁrst
20 nts located near the 5′ end of an exon, nts 21–40
near the 5′ end of an exon, the ﬁrst 20 nts near the 3′
end of an exon, and nts 21–40, starting from the 3′ exon
region (ﬁg 1b). Because the number of missensemutations
located in these speciﬁc regions is relatively low, we com-
bined the data on both the hMLH1 and hMSH2 genes.
We found that 180% of pathogenic missense mutations
that are located in the last 20 nts of exons (especially in
short exons—80 nts, on average) strongly colocalize with
ESEs (ﬁg. 1b). This ﬁnding suggests that functional ESEs
are preferentially located near the 3′ ends of exons. How-
ever, since we used mostly short exons (∼80 nts), it is
noteworthy that, in fact, the functional ESEs are located
60–65 nts from the 5′ ends of exons.
Aside from the SR proteins that we have studied here,
other classes of exonic enhancers exist; for example, those
driven by hnRNP proteins (Chabot et al. 2003). In future
research, studies of the frequency of mutations that af-
fect other ESE sites would be of interest, once algorithms
have been developed for evaluating the effect that mu-
tations have on splicing related to these proteins. In sum-
mary, our analyses provide compelling evidence thatmany
missense mutations associated with deleterious effects
for hMLH1 and hMSH2 affect splicing. Of note, we
found that conservative mutations that heretofore may
not have had an obvious role in causing HNPCC may
disrupt splicing. Further studies to evaluate the isoforms
of mRNAs in individuals withmissensemutations in ESE
sites would help to conﬁrm the role of missense muta-
tions in disease causation and to provide clinical insight
into the signiﬁcance of these mutations.
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